Based on the above mechanism, the outcome of anti‐PD‐1/PD‐L1 immunotherapy should be predicted by tumour neoantigen level, the level of tumour infiltrating lymphocytes (TILs) and cancer/TME PD‐L1 expression. This evidence concerns the gene PDCD1 and cancer.